Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277980 | 1.00 | VCP (0.35) | VCPSYK | |
| SCHEMBL1278033 | 0.93 | VCP (0.33) | VCP | |
| SCHEMBL1278030 | 0.93 | VCP (0.33) | VCP | |
| SCHEMBL1277859 | 0.91 | ALOX15 (0.35) | VCP | |
| SCHEMBL1277857 | 0.91 | ALOX15 (0.35) | VCP | |
| SCHEMBL1278097 | 0.89 | LTA4H (0.32) | — | |
| SCHEMBL3029381 | 0.89 | LTA4H (0.32) | — | |
| SCHEMBL3023804 | 0.88 | THRB (0.34) | VCPSYK | |
| SCHEMBL3023805 | 0.88 | THRB (0.34) | VCPSYK | |
| SCHEMBL1278008 | 0.86 | VCP (0.33) | VCPSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309586-B2 | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | LG LIFE SCIENCES LTD. (KR) | 2012-11-13 | — | — | US | claimed |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG CHEM, LTD. (KR) | 2012-04-12 | — | — | US | claimed |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | claimed |
| EP-2220081-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2010-08-25 | — | — | EP | claimed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | claimed |
| US-10322135-B2 | Pharmaceutical composition comprising indole compound | LG CHEM, LTD. (KR) | 2019-06-18 | — | — | US | disclosed |
| US-20170165272-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-8309586-B2 | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | LG LIFE SCIENCES LTD. (KR) | 2012-11-13 | — | — | US | disclosed |
| EP-2493469-A2 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE COMPOUND | LG Life Sciences Ltd (KR) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214804-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE COMPOUND | LG CHEM, LTD. (KR) | 2012-08-23 | — | — | US | disclosed |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG CHEM, LTD. (KR) | 2012-04-12 | — | — | US | disclosed |
| WO-2011052950-A2 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-05-05 | — | — | WO | disclosed |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | disclosed |
| EP-2220081-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009082152-A2 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214804-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE COMPOUND | IDO1, IDO2, AIFM1 | VCP 3462/4885SYK 4064/4885 |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCKR, GCK, GALK1 | VCP 3418/4885SYK 808/4885 |
| US-10322135-B2 | Pharmaceutical composition comprising indole compound | IDO1, IDO2, AIFM1 | VCP 3462/4885SYK 4064/4885 |
| US-20170165272-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE COMPOUND | TFAM, IDO1, AIFM1 | VCP 3136/4885SYK 4171/4885 |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCK, GCKR, HK1 | VCP 2525/4885SYK 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.